Alzheimer Disease Blood Biomarkers - Who Should Be Tested?
July 18, 2026
Welcome to the new format of Greg’s Alzheimer’s Research Report.
Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.
On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.
Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.
This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:
Monthly Subscription: $10 per month
Annual Subscription: $100 per year (Save $20 annually)
Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)
SUMMARY
Blood-based biomarkers of Alzheimer disease pathology have advanced rapidly recently, and are now increasingly used in research, clinical trials, and clinical practice. Blood-based biomarkers promise to improve accurate diagnosis of Alzheimer disease, with the potential for much greater reach than cerebrospinal fluid or PET tests. Yet, there are current clinical limitations to blood-based biomarkers.
